Cristian Ioan I.

Advances in targeted therapy for HER2‑positive metastatic breast cancer and aggressive lung malignancies.

• trastuzumab deruxtecan with or without pertuzumab
• tarlatamab after chemoradiotherapy for limited‑stage small‑cell lung cancer
• V940 combined with pembrolizumab in resectable cutaneous squamous cell carcinoma

Efforts emphasize precision medicine, antibody‑drug conjugates, and immunotherapy combinations.

Therapeutic exploration in severe chronic obstructive pulmonary disease and acute respiratory syndromes.

• astégolimab to reduce COPD exacerbations
• CAL02 adjunctive therapy for severe community‑acquired bacterial pneumonia
• investigational inhaled agents for pulmonary hypertension associated with interstitial lung disease

Studies target airway inflammation, infection‑related lung injury, and vascular complications of lung disease.

Interventions aimed at modulating immune activity in Crohn’s disease and ulcerative colitis.

• AZD7798 induction for Crohn’s disease activity remission
• SAR441566 dose‑response evaluation in moderate to severe Crohn’s disease
• balinatunfib long‑term safety in Crohn’s disease and ulcerative colitis

Research focuses on cytokine inhibition, novel oral agents, and maintenance of mucosal healing.

Clinical investigation of disease‑modifying approaches for multiple sclerosis and refractory epilepsy.

• BIIB091 monotherapy and combination with diroximel fumarate in relapsing multiple sclerosis
• IMU‑838 efficacy in relapsing‑remitting multiple sclerosis
• extended‑release levetiracetam for drug‑resistant focal onset seizures

Efforts aim to reduce central nervous system inflammation and improve seizure control.